Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Otto Metzger

Showing results (11-20 of 92) with videos related to

Pageof 10
Sort By:
Critical Reviews in Oncology/Hematology|February 9, 2010
Genomic Grade Index: An important tool for assessing breast cancer tumor grade and prognosisOtto Metzger Filho, Michail Ignatiadis, Christos Sotiriou
The Oncologist|December 23, 2018
Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical TrialsJosé Pérez-Garcia, Javier Cortés, Otto Metzger Filho
Oncology (Williston Park, N.Y.)|September 11, 2012
The natural history of hormone receptor-positive breast cancerElgene Lim, Otto Metzger-Filho, Eric P Winer
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2013
Pertuzumab: optimizing HER2 blockadeOtto Metzger-Filho, Eric P Winer, Ian Krop
Ecancermedicalscience|May 2, 2015
Treatment of early-stage HER2+ breast cancer-an evolving fieldArlindo R Ferreira, Kamal S Saini, Otto Metzger-Filho
Expert Opinion on Investigational Drugs|July 17, 2009
Larotaxel: broadening the road with new taxanesOtto Metzger-Filho, Camilo Moulin, Evandro de Azambuja, et al.
Drug Safety|December 6, 2011
Benefit-risk assessment of bevacizumab in the treatment of breast cancerRodrigo Dienstmann, Felipe Ades, Kamal S Saini, et al.
Critical Reviews in Oncology/Hematology|September 7, 2010
Prevention and management of major side effects of targeted agents in breast cancerOtto Metzger Filho, Kamal S Saini, Hatem A Azim, et al.
Investigational New Drugs|March 15, 2012
Clinical development of insulin-like growth factor receptor--1 (IGF-1R) inhibitors: at the crossroad?Andrea Gombos, Otto Metzger-Filho, Lissandra Dal Lago, et al.
Frontiers in Oncology|February 9, 2018
Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer with Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02)Arlindo R Ferreira, Otto Metzger-Filho, Roberta M B Sarmento, et al.
Pageof 10

Showing results (11-20 of 92) with videos related to

Sort By:
Pageof 10
Critical Reviews in Oncology/Hematology|February 9, 2010
Genomic Grade Index: An important tool for assessing breast cancer tumor grade and prognosisOtto Metzger Filho, Michail Ignatiadis, Christos Sotiriou
The Oncologist|December 23, 2018
Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical TrialsJosé Pérez-Garcia, Javier Cortés, Otto Metzger Filho
Oncology (Williston Park, N.Y.)|September 11, 2012
The natural history of hormone receptor-positive breast cancerElgene Lim, Otto Metzger-Filho, Eric P Winer
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2013
Pertuzumab: optimizing HER2 blockadeOtto Metzger-Filho, Eric P Winer, Ian Krop
Ecancermedicalscience|May 2, 2015
Treatment of early-stage HER2+ breast cancer-an evolving fieldArlindo R Ferreira, Kamal S Saini, Otto Metzger-Filho
Expert Opinion on Investigational Drugs|July 17, 2009
Larotaxel: broadening the road with new taxanesOtto Metzger-Filho, Camilo Moulin, Evandro de Azambuja, et al.
Drug Safety|December 6, 2011
Benefit-risk assessment of bevacizumab in the treatment of breast cancerRodrigo Dienstmann, Felipe Ades, Kamal S Saini, et al.
Critical Reviews in Oncology/Hematology|September 7, 2010
Prevention and management of major side effects of targeted agents in breast cancerOtto Metzger Filho, Kamal S Saini, Hatem A Azim, et al.
Investigational New Drugs|March 15, 2012
Clinical development of insulin-like growth factor receptor--1 (IGF-1R) inhibitors: at the crossroad?Andrea Gombos, Otto Metzger-Filho, Lissandra Dal Lago, et al.
Frontiers in Oncology|February 9, 2018
Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer with Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02)Arlindo R Ferreira, Otto Metzger-Filho, Roberta M B Sarmento, et al.
Pageof 10